{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011778","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.255029+00:00","generated_at":"2026-05-17T09:37:25.434139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth","bullets":["Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).","FY net sales $1,296.2M (+27%), adj. EBITDA $183.7M (+65%), adj. diluted EPS $2.09 (+76%).","Zoetis MFA portfolio contributed $94.5M incremental revenue in Q4 and $208.2M for full year.","FY2026 guidance: net sales $1.43-1.48B, adj. EBITDA $225-235M (25% growth), adj. EPS $2.52-2.70.","Gross leverage 3.1x as of June 30, 2025; free cash flow $41.8M for the year."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011778","json":"https://secwatch.observer/filing/0001558370-25-011778.json","markdown":"https://secwatch.observer/filing/0001558370-25-011778.md","text":"https://secwatch.observer/filing/0001558370-25-011778.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/0001558370-25-011778-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/pahc-20250827x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:37:25.434139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}